Rimonabant-induced apoptosis in leukemia cell lines: Activation of caspase-dependent and -independent pathways

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 370-380

  Gallotta, Dario ^a   Nigro, Patrizia ^a   Cotugno, Roberta ^a   Gazzerro, Patrizia ^a   Bifulco, Maurizio ^a   Belisario, Maria Antonietta ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PROTEIN KINASE B; RIMONABANT;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN MODIFICATION;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; JURKAT CELLS; LEUKEMIA; PIPERIDINES; PYRAZOLES; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 77953357802     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.023     Document Type: Article

References (52)

1. Bifulco M., Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Nat Med 2002, 8:547-550.
2. De Petrocellis L., Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009, 23:1-15.
3. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009, 60:77-84.
4. Bifulco M. The endocannabinoid system: from biology to therapy. Pharmacol Res 2009, 60:75-76.
5. Bifulco M., Laezza C., Pisanti S., Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006, 148:123-135.
6. Pisanti S., Malfitano A.M., Grimaldi C., Santoro A., Gazzerro P., Laezza C., et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 2009, 23:117-131.
7. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., DI Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 2004, 18:1606-1608.
8. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006, 318:1375-1387.
9. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006, 312:363-373.
10. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003, 17:1771-1773.
11. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide. Correlation to its tumour-suppressor efficacy. J Cell Physiol 2007, 211:495-503.
12. Bifulco M., Gazzerro P., Laezza C., Pentimalli F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Oncol Rep 2007, 17:813-816.
13. Laezza C., Pisanti S., Malfitano A.M., Bifulco M. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signalling pathway. Endocr Relat Cancer 2008, 15:965-974.
14. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002, 100:627-634.
15. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 2000, 275:31938-31945.
16. Sarker K.P., Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 2003, 60:1200-1208.
17. Rinaldi-Carmona M., Barth F., Healume M., Shire D., Calandra B., Congy C., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
18. Sarnataro D., Pisanti S., Santoro A., Gazzerro P., Malfitano A.M., Laezza C., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2007, 70:1298-1306.
19. Malfitano A.M., Laezza C., Pisanti S., Gazzerro P., Bifulco M. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol 2008, 153:1003-1010.
20. Flygare J., Gustafsson K., Kimby E., Christensson B., Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 2005, 579:6885-6889.
21. Gazzerro P., Malfitano A.M., Proto M.C., Santoro A., Pisanti S., Caruso M.G., et al. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep 2010, 23:171-175.
22. Bifulco M., Santoro A., Laezza C., Malfitano A.M. Cannabinoid receptor CB1 antagonists state of the art and challenges. Vitam Horm 2009, 81:159-189.
23. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279.
24. Scaduto R.C., Grotyohann L.W. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999, 76:469-477.
25. Rothe G., Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'-dichlorofluorescin. J Leukoc Biol 1990, 47:440-448.
26. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria as targets for chemotherapy. Apoptosis 2009, 14:624-640.
27. 2+: a control point for apoptosis. Science 2003, 300:135-139.
28. Li M., Kondo T., Zhao Q.L., Li F.J., Tanabe K., Arai Y., et al. Apoptosis induced by cadmium in human lymphoma U937 cells through Ca2+-calpain and caspase-mitochondria-dependent pathways. J Biol Chem 2000, 275:39702-39709.
29. Arai Y., Kondo T., Tanabe K., Zhao Q.L., Li F.J., Ogawa R., et al. Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells. J Biol Chem 2002, 277:18986-18993.
30. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
31. Cao G., Xing J., Xiao X., Liou A.K., Gao Y., Yin X.M., et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 2007, 27:9278-9293.
32. Vandenabeele P., Vanden Berghe T., Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006, 2006:pe44.
33. Yu S.W., Andrabi S.A., Wang H., Kim N.S., Poirier G.G., Dawson T.M., et al. Apoptosis-inducing factor mediates poly(ADPribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006, 103:18314-18319.
34. Hassa P.O. The molecular " Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front Biosci 2009, 14:72-111.
35. Imre G., Dunai Z., Petak I., Mihalik R. Cystein cathepsin and Hsp90 activities determine the balance between apoptotic and necrotic cell death pathways in caspase-compromised U937 cells. Biochim Biophys Acta 2007, 1773:1546-1557.
36. Chaitanya G.V., Babu P.P. Differential PARP cleavage: an indication of heterogeneous forms of cell death and involvement of multiple proteases in the infarct of focal cerebral ischemia in rat. Cell Mol Neurobiol 2009, 29:563-573.
37. Yu H.G., Ai Y.W., Yu L.L., Zhou X.D., Liu J., Li J.H., et al. Phosphoinositide 3-kinase/AKT pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008, 122:433-443.
38. Oh J.H., Lee T.J., Kim S.H., Choi Y.H., Lee S.H., Lee J.M., et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of AKT phosphorylation. Apoptosis 2008, 13:1494-1504.
39. de Frias M., Iglesias-Serret D., Cosialls A.M., Coll-Mulet L., Santidrián A.F., González-Gironès D.M., et al. AKT inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica 2009, 94:1698-1707.
40. Eapen A.K., Henry M.K., Quelle D.E., Quelle F.W. DNA damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol Cell Biol 2001, 21:6113-6121.
41. Yu C., Mao X., Li W.X. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005, 331:391-397.
42. Powles T., te Poele R., Shamash J., Chaplin T., Propper D., Joel S., et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 2005 Feb 1, 105(3):1214-1221.
43. Jaattela M., Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003, 4:416-423.
44. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009, 16:3-11.
45. Athanasiou A., Smith P.A., Vakilpour S., Kumaran N.M., Turner A.E., Bagiokou D., et al. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochem Biophys Res Commun 2007, 354:50-55.
46. Athanasiou A., Clarke A.B., Turner A.E., Kumaran N.M., Vakilpour S., Smith P.A., et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 2007, 364:131-137.
47. Boujrad H., Gubkina O., Robert N., Krantic S., Susin S.A. AIF-mediated programmed necrosis: a highly regulated way to die. Cell Cycle 2007, 6:2612-2619.
48. Wang Y., Dawson V.L., Dawson T.M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009, 218:193-202.
49. Wang Y., Kim N.S., Li X., Greer P.A., Koehler R.C., Dawson V.L., et al. Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos). J Neurochem 2009, 110:687-696.
50. Heeres P.T., Hergenrother P.J. Poly(ADP-ribose) makes a date with death. Curr Opin Chem Biol 2007, 11:644-653.
51. Lee N.S., Cheong H.J., Kim S.J., Kim S.E., Kim C.K., Lee K.T., et al. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 2003, 17:1375-1383.
52. Kornacker M., Stumm J., Pott C., Dietrich S., Süssmilch S., Hensel M., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 2009, 20:722-728.